Ancora Biotech
Business Services · California, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
Newark, California, 94560, United StatesWebsite
www.ancorabiotech.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About Ancora Biotech
Ancora Biotech LLC is a privately held company supporting the clinical development of three multi-specific antibodies. These three antibodies are held in separate spin-offs, namely: 1) TeneoTwo holds the company's clinical stage TNB-486 (anti-CD19xCD3) T cell engager for the safe and effective treatment of B cell cancers, 2) TeneoFour holds the company's preclinical TNB-738 (anti-CD38) enzyme inhibitor for the treatment of inflammatory and metabolic disorders in the elderly, and 3) TeneoTen holds the company's preclinical T cell engager (anti-HBVxCD3) for the curative treatment of chronic hepatitis B infections (CHB). TNB-738 is poised to enter Phase I clinical studies by early 2022 and the company anticipate to select a clinical lead for CHB by mid-2022.Explore more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Ancora Biotech your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Ancora Biotech, which may be a good buyer, showed buying intent in Masked Content Topic
Funding: Get notified immidiatlly once Ancora Biotech has new funding data
Click to see if Ancora Biotech had a recent Job posting/layoffs
Product Launch: Get notified when Ancora Biotech launches new products
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Earning: See what the market has to say on Ancora Biotech recently announced quarterly report
Check if Ancora Biotech has recently received funding, and reach out quickly before it becomes old news!
Congratulate Masked Content for being promoted to Masked Content at Ancora Biotech
Website visits: Recent activity has been detected on your website
Check out if Ancora Biotech is spiking on competitors!
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 2 more new buyers
Compare Similar Companies to Ancora Biotech
Compare insights from companies similar to Ancora Biotech, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Ancora Biotech
<$5M
1-10
Private
$60M
2022
N/A
Company Profile Activity
Activity Insights
Ancora Biotech is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Ancora Biotech is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Ancora Biotech.
Ancora Biotech financials insights
Gather financial insights about Ancora Biotech, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2022
Series A
$60M
Ancora Biotech Tech Stack
A closer look at the technologies used by Ancora Biotech
Top Business Services Companies
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Ancora Biotech
Sign Up For FreeTo access detailed company insights
Ancora Biotech LLC is a privately held company supporting the clinical development of three multi-specific antibodies. These three antibodies are held in separate spin-offs, namely: 1) TeneoTwo holds the company's clinical stage TNB-486 (anti-CD19xCD3) T cell engager for the safe and effective treatment of B cell cancers, 2) TeneoFour holds the com... Read More
